GSK Responds to FDA Decision on Avandia (rosiglitazone)

GSK plc [LSE/NYSE: GSK] announced today that the U.S. Food and Drug Administration (FDA) has eased restrictions on patient access to Avandia (rosiglitazone), following an FDA Advisory Committee review in June 2013.
Source: GSK news - Category: Pharmaceuticals Source Type: news